FDA Approves Ketamine Nasal Spray as First and Only Standalone Therapy for Treatment-Resistant Depression
Veriheal
JUNE 12, 2025
In January, the US Food and Drug Administration (FDA) approved the Johnson & Johnson brand nasal spray, Spravato®, as the world’s first and only monotherapy for addressing treatment-resistant cases of major depressive disorder (MDD). However, doctors do not consider esketamine a first-line treatment for depression.
Let's personalize your content